ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1158

Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up

Kaleb Michaud1, Sofia Pedro2, Victoria Jasion3, Holly Budlong4, Jessica Suboticki5, Frederick Wolfe6 and Patricia Katz7, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3AbbVie, Overland Park, KS, 4AbbVie, Minneapolis, MN, 5AbbVie Inc., North Chicago, IL, 6National Data Bank for Rheumatic Diseases, Wichita, KS, 7University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2021

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), health behaviors, longitudinal studies, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness to change treatment and reasons for not changing have shifted by repeating a pivotal study questionnaire 15 years later.1

Methods: Data are from participants with RA enrolled in FORWARD, The National Databank for Rheumatic Diseases, a longitudinal registry of individuals with rheumatic diseases. Patients answered 9 questions on treatment satisfaction and preferences in 2006 (Y06) and/or 2021 (Y21). Questions included an overall assessment of likelihood to change therapy (Q1, “As long as I don’t get worse I wouldn’t want to change my arthritis medications,” rated as true-false) and 8 (Q2-Q9) evaluating reasons for (un)willingness to change (Table 1). Paired McNemar tests were performed in the subset who answered the questionnaire at both Y06 and Y21 to estimate the likelihood of willingness to change therapy at Y21 based on response at Y06. Logistic regression was used to identify predictors at both time points of responses to Q1.

Results: In 2006, 6282 responders had a mean age of 63 years, 17 years RA duration, and exposure to 3 (IQR 2-5) DMARDs. As of April 2021, 1632 responders had a mean age of 66 years, 24 years RA duration, and exposure to 4 (IQR 3-5) DMARDs. Overall for Y06, 64% did not want to change therapy as long as their condition didn’t get worse, compared with 51% from Y21. However, when looking at responses of those who completed both Y06 and Y21 questionnaires (n=442), there were no significant differences in willingness to change therapy. The primary reasons for unwillingness to change therapy over time (Y06 vs Y21) were as follows: satisfaction with medication (53% vs 37%), risk of side effects (72% vs 43%), and doctor recommendation (71% vs 38%) (Table 1). In the paired group, those who provided a reason for not changing in Y21 (eg, side effects) were more likely to have provided the same reason in Y06 (eg, 4.7-fold increase for side effects; Figure 1). Predictors of unwillingness to change therapy in Y06 and Y21 included the following: satisfactory control of RA, risk of side effects, fearing loss of control, doctor thinking current medications were best, and lower levels of pain (Table 2). Predictors related to cost or insurance were associated with unwillingness to change in Y06, but not in Y21.

Conclusion: While the overall proportion of respondents who were unwilling to change therapies was lower in 2021 than in 2006, analysis of those who responded to both questionnaires showed little change. In addition, the major reasons given for not wanting to change therapies did not change from 2006 to 2021, although cost and hassle with insurance companies were no longer significant predictors in 2021. Further data are needed to understand whether the correlation between (un)willingness to change treatments and disease activity and clinical outcomes has evolved over time.

Reference:
1. Wolfe F, Michaud K. Arthritis Rheum 2007;56(7):2135-42.

Table 1. Treatment predictors and preference for not changing therapy

Figure 1. Odds (95% CI) of being unwilling to change medications at Y21 if unwilling to change at Y06.

Table 2. Multivariable predictors of unwillingness to change therapy outcome in overall and paired samples.


Disclosures: K. Michaud, None; S. Pedro, FORWARD, the National Data Bank for Rheumatic Diseases, 3; V. Jasion, AbbVie, 3, 11; H. Budlong, AbbVie, 3, 11; J. Suboticki, AbbVie, 3, 11; F. Wolfe, None; P. Katz, None.

To cite this abstract in AMA style:

Michaud K, Pedro S, Jasion V, Budlong H, Suboticki J, Wolfe F, Katz P. Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/resistance-of-patients-with-rheumatoid-arthritis-to-changing-therapy-a-15-year-follow-up/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resistance-of-patients-with-rheumatoid-arthritis-to-changing-therapy-a-15-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences